Exogenous administration of ADM and CGRP peptides or their gene delivery is a new preventive and therapeutic strategy for cardiovascular diseases such as hypertension, myocardial ischemia, heart failure, and renal failure [11, 59, 60]. The gene discussed is ADM; the disease is acute kidney injury.